Edition:
United States

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

114.88USD
25 May 2018
Change (% chg)

$-7.76 (-6.33%)
Prev Close
$122.64
Open
$120.17
Day's High
$120.17
Day's Low
$110.52
Volume
95,767
Avg. Vol
84,601
52-wk High
$154.35
52-wk Low
$13.11

Latest Key Developments (Source: Significant Developments)

Madrigal Pharmaceuticals Qtrly ‍Loss Per Share $0.67​
Tuesday, 13 Mar 2018 06:50am EDT 

March 13 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, REVIEWS KEY CORPORATE ACHIEVEMENTS AND PROVIDES CLINICAL UPDATE ON MGL-3196.MADRIGAL PHARMACEUTICALS INC - QTRLY ‍LOSS PER SHARE $0.67​.MADRIGAL PHARMACEUTICALS INC - CO IS IN A "STRONG" FINANCIAL POSITION TO ADVANCE MGL-3196 IN BOTH INDICATIONS​.  Full Article

Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia
Thursday, 8 Feb 2018 06:50am EST 

Feb 8 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH).MADRIGAL PHARMACEUTICALS- STATISTICALLY SIGNIFICANT IMPROVEMENT ACHIEVED IN REDUCTION OF LDL CHOLESTEROL (LDL-C) WITH MGL-3196 COMPARED TO PLACEBO.MADRIGAL PHARMACEUTICALS INC - MGL-3196 WAS WELL TOLERATED IN THE TRIAL AS COMPARED TO PLACEBO.MADRIGAL PHARMACEUTICALS- LDL-C LOWERING WAS 28.5% IN MGL-3196 TREATED VERSUS PLACEBO IN PRESPECIFIED GROUP OF PATIENTS WHO DIDNT TOLERATE HIGH INTENSITY STATIN DOSES.MADRIGAL PHARMACEUTICALS- THERE WERE 2 SERIOUS ADVERSE EVENTS IN STUDY, BOTH UNRELATED TO TREATMENT, ONE IN A PLACEBO AND ONE IN A DRUG-TREATED PATIENT.  Full Article

Madrigal Pharmaceuticals Prices Public Offering Of Common Stock
Monday, 18 Dec 2017 11:26pm EST 

Dec 18 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.MADRIGAL PHARMACEUTICALS INC SAYS PRICES OFFERING OF 1.5 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $83.00 PER SHARE.  Full Article

Madrigal Pharma Announces Proposed Public Offering Of Common Stock
Monday, 18 Dec 2017 06:50am EST 

Dec 18 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.MADRIGAL PHARMACEUTICALS INC - ‍COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $100 MILLION OF ITS COMMON STOCK​.  Full Article

Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial
Wednesday, 6 Dec 2017 06:55am EST 

Dec 6 (Reuters) - Madrigal Pharmaceuticals Inc ::MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PHASE 2 CLINICAL TRIAL.MADRIGAL PHARMACEUTICALS INC - MGL-3196 HAS BEEN WELL-TOLERATED WITH MOSTLY MILD AES, AND A FEW MODERATE AES IN STUDY.MADRIGAL PHARMACEUTICALS INC - THERE HAVE BEEN THREE SERIOUS ADVERSE EFFECTS IN STUDY, ALL CONSIDERED UNRELATED TO MGL-3196.MADRIGAL PHARMACEUTICALS - IN TRIAL, MGL-3196 DEMONSTRATED STATISTICALLY SIGNIFICANT RESULTS FOR THE PRIMARY ENDPOINT.  Full Article

Madrigal Pharmaceuticals reports Q3 loss per share of $0.68
Thursday, 9 Nov 2017 07:50am EST 

Nov 9 (Reuters) - Madrigal Pharmaceuticals Inc :Madrigal Pharmaceuticals reports 2017 third quarter financial results.Qtrly loss per share $0.68 ‍​.‍As of Sept 30, had cash, cash equivalents and marketable securities of $62.1 million, versus $40.5 million at December 31, 2016​.On track to report top-line results for nash late this year and hefh early in 2018​.  Full Article

Madrigal Pharmaceuticals reports qtrly loss per share $0.69‍​
Thursday, 10 Aug 2017 08:50am EDT 

Aug 10 (Reuters) - Madrigal Pharmaceuticals Inc ::Madrigal Pharmaceuticals reports 2017 second quarter financial results.Qtrly loss per share $0.69‍​.  Full Article

Madrigal Pharma completes Phase 2 enrollment for study on treatment of NASH
Tuesday, 1 Aug 2017 07:30am EDT 

Aug 1 (Reuters) - Madrigal Pharmaceuticals Inc :Completes enrollment in Phase 2 proof-of-concept study with MGL-3196 for treatment of NASH.On track to release top-line results for primary endpoint, reduction of liver fat assessed by MRI-PDFF at 12 weeks by end of year​.Will be on track to provide top-line 36 week results, which include final MRI-PDFF, end-of-study liver biopsy, in Q2 of 2018​.Data from phase 2 study with MGL-3196 in heterozygous familial hypercholesterolemia to also become available by year end or very early in 2018​.  Full Article

Madrigal Pharma announces $35 million private placement offering
Wednesday, 21 Jun 2017 09:00am EDT 

June 21 (Reuters) - Madrigal Pharmaceuticals Inc :Madrigal pharmaceuticals announces $35 million private placement offering.Madrigal pharmaceuticals inc - private placement offering of approximately 328,300 shares of common stock.Madrigal pharmaceuticals inc - private placement offering of approximately 1.97 million shares of its series a convertible preferred stock.Madrigal pharmaceuticals inc says expects to use proceeds from offering primarily to support ongoing clinical development of its lead compound, mgl-3196.  Full Article

Madrigal Pharmaceuticals says DSMC for clinical studies of MGL-3196 held a pre-scheduled meeting to review data from Phase 2 clinical nash trial
Thursday, 1 Jun 2017 06:10am EDT 

June 1 (Reuters) - Madrigal Pharmaceuticals Inc :Madrigal Pharmaceuticals - ‍on May 26, DSMC for clinical studies of co's MGL-3196 held a pre-scheduled meeting to review data from Phase 2 clinical nash trial.Madrigal Pharmaceuticals - ‍DSMC recognized co for progress on clinical trial and recommended co continue clinical trial with no changes to protocol.Madrigal Pharmaceuticals Inc - intends to proceed with clinical trial in accordance with DSMC's recommendation​.Madrigal Pharmaceuticals Inc - ‍expects to have top-line results for primary endpoint of study, reduction of liver fat, at 12 weeks, by year-end 2017​.  Full Article

BRIEF-Madrigal Pharmaceuticals Reports Qtrly Loss Per Share Of $0.45

* MADRIGAL PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND REVIEWS KEY CLINICAL ACHIEVEMENTS